Latest:
Dr McAndrew on a Subgroup Analysis of NATALEE in HR+/HER2– Early Breast Cancer
Nicholas P. McAndrew, MD, MSCE, discusses a subgroup analysis of the NATALEE trial in HR+/HER2– early breast cancer by prior systemic treatment.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Nichole Tucker
Latest:
Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation
The smoldering multiple myeloma treatment paradigm harbors fractures in the consensus regarding the optimal management of this disease, with some experts favoring a watch-and-wait approach and others advocating for early treatment.
Nick Rose
Latest:
The Virtual Window: Clinical Trial Reports--March 2007
Successful research into new therapies for cancer requires a ready supply of patients willing to participate in clinical trials, and physicians and other health care professionals who will refer their patients to the appropriate studies.
Nick Sambides, Jr
Latest:
Oncology Practices Face the Biggest Change in Coding Since the Computer-ICD-10
Set for full rollout on October 1, the much delayed 10th revision of the International Statistical Classification of Diseases and Related Health Problems is probably the biggest revision to medical coding and billing since computerized medical coding and billing practices began decades ago.
Nickolas Papadopoulos, PhD
Latest:
Results of a Combined Modality Screening Approach in Women Without Cancer History
Nickolas Papadopoulos, PhD, professor of oncology and pathology, Johns Hopkins University School of Medicine, discusses the results of a study which evaluated a combined modality screening approach in women without a history of cancer.
Nicola Normanno, MD
Latest:
Dr. Normanno on Using Circulating Tumor DNA for EGFR Detection
Nicola Normanno, MD, chief of the Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Naples, Italy, discusses the benefit of plasma genotyping to predict response to EGFR-targeted therapy in patients with non-small cell lung cancer (NSCLC).
Nikhil C. Munshi, MD
Latest:
Dr Munshi on the Background of the CARTITUDE-1 Trial in Multiple Myeloma
Nikhil C. Munshi, MD, discusses the background of the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and highlights the specific patient population enrolled in the study.